Regeneron swoops on genetic testing firm 23andMe
DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
Tariff turbulence: Navigating US trade shifts in the medtech...
The US has been at the centre of a shift in global trade dynamics these last few weeks, resulting from a rise in geopolitical and economic uncertainty.
Japan follows UK in GSK's comeback tour for Blenrep
The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.
Featured Content
Editor's Picks
Editor's Picks
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
4th Annual Process Development for Cell Therapies Summit
Driving Process Robustness, Scalability, Speed & Affordability
Operationalize: Expanded Access Programs comes to the West C...
Improving Global Access to Life-Changing Therapeutics...
Injectable Drug Delivery 2025 – Driving Innovation Through C...
Press Release: Injectable Drug Delivery 2025 – Driving Innovation Through Collaboration LONDON, UK – 24–25 June 2025
4th In Vivo Cell Engineering & Gene Editing Summit
This forum brings together the brightest minds from biopharma, academia, and regulatory leadership to explore the full translational journey
6th Gene Therapy Analytical Development Summit Europe
Join 24+ expert speakers and over 90 industry stakeholders to unlock analytical strategies that elevate your development programmes,...